Huang Jian-Da, Gu Tong-Jie, Hu Zhi-Lin, Zhou Dan-Fei, Ying Jun
Department of Respiration, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, China.
Comb Chem High Throughput Screen. 2019;22(3):160-168. doi: 10.2174/1386207322666190415101408.
The study aimed to evaluate the efficacy and safety of invasivenoninvasive sequential ventilation versus invasive ventilation in the treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
PubMed, Cochrane, Embase, Wanfang, CNKI, VIP database were searched by the index words to identify the qualified RCTs, and relevant literature sources were also searched. The latest research was conducted in June 2017. Relative Risks (RR), and Mean Difference (MD) along with 95% confidence interval (95% CI) were used to analyze the main outcomes.
Twenty-nine RCTs were involved in this analysis of 1061 patients in the invasivenoninvasive sequential ventilation group (In-non group) and 1074 patients in the invasive ventilation group (In group). The results indicated that compared with the invasive ventilation, invasive-noninvasive sequential ventilation would significantly decrease the incidence of VAP (RR:0.20, 95%CI: 0.16-0.26), mortality (RR:0.38, 95%CI: 0.26-0.55), reintubation (RR:0.39, 95%CI: 0.27-0.55); and statistically reduced the duration of invasive ventilation (MD:-9.23, 95%CI: -10.65, -7.82), the total duration of mechanical ventilation (MD:-4.91, 95%CI: -5.99, -3.83), and the length of stay in the ICU (MD:-5.10, 95%CI: -5.43, -4.76).
The results demonstrated that the application of noninvasive sequential ventilation after invasive ventilation at the pulmonary infection control window has a significant influence on VAP incidence, mortality, and the length of stay in the ICU, but further well-designed, adequately powered RCTs are required to validate the conclusion.
本研究旨在评估有创-无创序贯通气与有创通气治疗慢性阻塞性肺疾病急性加重期(AECOPD)的疗效和安全性。
通过关键词检索PubMed、Cochrane、Embase、万方、知网、维普数据库以识别合格的随机对照试验(RCT),并检索相关文献来源。最新研究时间为2017年6月。采用相对危险度(RR)、平均差(MD)及95%置信区间(95%CI)分析主要结局。
本分析纳入了29项RCT,有创-无创序贯通气组(In-non组)1061例患者,有创通气组(In组)1074例患者。结果表明,与有创通气相比,有创-无创序贯通气可显著降低呼吸机相关性肺炎(VAP)发生率(RR:0.20,95%CI:0.16 - 0.26)、死亡率(RR:0.38,95%CI:0.26 - 0.55)、再插管率(RR:0.39,95%CI:0.27 - 0.55);并在统计学上缩短了有创通气时间(MD:-9.23,95%CI:-10.65,-7.82)、机械通气总时间(MD:-4.91,95%CI:-5.99,-3.83)及重症监护病房(ICU)住院时间(MD:-5.10,95%CI:-5.43,-4.76)。
结果表明,在肺部感染控制窗期采用有创通气后序贯无创通气对VAP发生率、死亡率及ICU住院时间有显著影响,但需要进一步设计良好、样本量充足的RCT来验证该结论。